Full length large t tumor antigen of merkel cell polyomavirus as a therapeutic target in merkel cell carcinoma
AssigneeInstitut Curie
InventorsMartine PETER, Xavier SASTRE-GARAU
Life of this patent
Estimating the term…
Abstract
The invention relates to a full length Large T tumor antigen of Merkel Cell Polyomavirus (MCV) as a therapeutic target in Merkel Cell Carcinoma (MCC).
Claims19
A virus-like particle (VLP) wherein said VLP is a polyomavirus comprising a nucleic acid sequence having at least 60% identity with SEQ ID NO:5 (exon 2 of large T antigen, LT) and wherein said VLP has been isolated from a patient, preferably a patient suffering from Merkel Cell Carcinoma (MCC) in an episomal form or integrated in the patient's genome.
An isolated nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11.
A isolated polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively.
An antibody which specifically recognizes the non-truncated LT protein.
A pharmaceutical composition comprising:
- a VLP according to and/or
- a nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11 and/or
- a polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively and/or
- an anti-MCV agent which is a molecule which specifically interacts with a nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11, or specifically interacts with a polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.